-
EP3732178
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3732178
| EP3732178 - BENZODIAZEPINE DERIVATIVES [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 27.10.2023 Database last updated on 14.06.2024 | |
| Former | Request for examination was made Status updated on 02.10.2020 | ||
| Former | The international publication has been made Status updated on 05.07.2019 | ||
| Former | unknown Status updated on 02.02.2019 | Most recent event Tooltip | 08.05.2024 | New entry: Reply to examination report | Applicant(s) | For all designated states ImmunoGen, Inc. 830 Winter Street Waltham, MA 02451 / US | [2020/45] | Inventor(s) | 01 /
MILLER, Michael Louis 4 Maymont Drive Framingham, MA 01701 / US | 02 /
SHIZUKA, Manami 253 Payson Road Belmont, MA 02478 / US | 03 /
CHARI, Ravi V.J. 174 Winchester Street Newton, MA 02461 / US | [2020/45] | Representative(s) | Marks & Clerk LLP 15 Fetter Lane London EC4A 1BW / GB | [N/P] |
| Former [2020/45] | McNab, Donald C. Marks & Clerk LLP 40 Torphichen Street Edinburgh EH3 8JB / GB | Application number, filing date | 18837084.5 | 27.12.2018 | [2020/45] | WO2018US67589 | Priority number, date | US201762611056P | 28.12.2017 Original published format: US 201762611056 P | US201862655523P | 10.04.2018 Original published format: US 201862655523 P | [2020/45] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019133652 | Date: | 04.07.2019 | Language: | EN | [2019/27] | Type: | A1 Application with search report | No.: | EP3732178 | Date: | 04.11.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 04.07.2019 takes the place of the publication of the European patent application. | [2020/45] | Search report(s) | International search report - published on: | EP | 04.07.2019 | Classification | IPC: | C07D471/04, C07D487/04, A61K31/5513, A61P35/00, A61K47/68 | [2020/45] | CPC: |
C07D487/04 (EP);
A61K47/6803 (EP,US);
A61K31/5513 (EP);
A61K45/06 (EP);
A61K47/68035 (EP);
A61K47/6851 (EP);
A61K47/6869 (EP,US);
A61K47/6889 (EP);
A61P35/00 (EP,US);
C07D471/04 (EP)
(-)
| C-Set: |
A61K31/5513, A61K2300/00 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/45] | Extension states | BA | 08.06.2020 | ME | 08.06.2020 | Validation states | KH | 08.06.2020 | MA | 08.06.2020 | MD | 08.06.2020 | TN | 08.06.2020 | Title | German: | BENZODIAZEPINDERIVATE | [2020/45] | English: | BENZODIAZEPINE DERIVATIVES | [2020/45] | French: | DÉRIVÉS DE BENZODIAZÉPINE | [2020/45] | Entry into regional phase | 08.06.2020 | National basic fee paid | 08.06.2020 | Designation fee(s) paid | 08.06.2020 | Examination fee paid | Examination procedure | 08.06.2020 | Examination requested [2020/45] | 08.06.2020 | Date on which the examining division has become responsible | 12.02.2021 | Amendment by applicant (claims and/or description) | 30.10.2023 | Despatch of a communication from the examining division (Time limit: M06) | 07.05.2024 | Reply to a communication from the examining division | Fees paid | Renewal fee | 28.12.2020 | Renewal fee patent year 03 | 27.12.2021 | Renewal fee patent year 04 | 27.12.2022 | Renewal fee patent year 05 | 27.12.2023 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]EP3100745 (IMMUNOGEN INC [US]) [X] 1-32,34-46,157-161 * claims 4,7; compounds 127 (IGN-11), 226, 228, 230 *; | [I]WO2017201132 (MERSANA THERAPEUTICS INC [US]) [I] 1-161 * Examples, claims *; | [XP]WO2017223275 (MERSANA THERAPEUTICS INC [US]) [XP] 1-161* Claims, example compounds *; | [XP]WO2018075842 (BRISTOL MYERS SQUIBB CO [US]) [XP] 1-161 * Claims, example compounds * | by applicant | US7557189734 | US3453266 | US3506646 | GB1476684 | US4062852 | US4444688 | JPH02138272 | WO9201047 | US5208020 | US5475092 | US5639641 | WO9906587 | US5885793 | US5969108 | WO0012508 | US6156746 | WO0220565 | US6441163 | WO03091232 | US6716821 | WO2004043344 | US2004132028 | WO2004069843 | WO2004103272 | WO2005009369 | US6913748 | US2005169933 | WO2005085260 | WO2006083275 | US2006182750 | US7101675 | WO2007015280 | WO2007024222 | US2007072846 | US2007082365 | WO2007062466 | WO2007085930 | US7276748 | US7276497 | US7276499 | US2007238667 | WO2007147213 | US2008050310 | US7342110 | US7368565 | US2008139791 | US7388026 | US2008152586 | US2008171040 | US7414073 | US2008305044 | EP2019104 | US2009082274 | US7557189 | US2009274713 | WO2009134976 | US2010129314 | US7772485 | US2010216708 | US2010255056 | US7811572 | US7834155 | US7855275 | US2011118146 | WO2011106528 | US2011224100 | WO2011112978 | US2011274623 | US2012009181 | US8119787 | WO2012058592 | WO2012058588 | US2012171115 | US2012238731 | US8337855 | US8435528 | US8557966 | US8709432 | US8765917 | - KAMAL A. et al., Bioorg. Med. Chem., (20080815), vol. 16, no. 16, pages 7804 - 10 | - KUMAR R, Mini Rev Med Chem., (20030600), vol. 3, no. 4, pages 323 - 39 | - KAMAL A et al., Current Med. Chem., (20020000), vol. 2, pages 215 - 254 | - WANG J-J., J. Med. Chem., vol. 49, pages 1442 - 1449 | - ALLEY M.C. et al., Cancer Res., (20040000), vol. 64, pages 6700 - 6706 | - PEPPER C. J., Cancer Res, (20040000), vol. 74, pages 6750 - 6755 | - THURSTON D.E.; BOSE D.S., Chem. Rev., (19940000), vol. 94, pages 433 - 465 | - TOZUKA, Z. et al., Journal of Antibiotics, (19830000), vol. 36, pages 1699 - 1708 | - S.G GREGSON et al., J. Med. Chem., (20010000), vol. 44, pages 737 - 748 | - M.C. ALLEY et al., Cancer Res., (20040000), vol. 64, pages 6700 - 6706 | - J.A. HARTLEY et al., Cancer Res., (20040000), vol. 64, pages 6693 - 6699 | - C. MARTIN et al., Biochemistry, (20050000), vol. 44, pages 4135 - 4147 | - S. ARNOULD et al., Mol. Cancer Ther., (20060000), vol. 5, pages 1602 - 1509 | - D. HOCHHAUSER et al., Clin. Cancer Res., (20090000), vol. 15, pages 2140 - 2147 | - The Chemistry of Heterocyclic Compounds, A series of Monographs, John Wiley & Sons, (19500000), vol. 13, 14, | - ISALM; DENT, Bioconjugation, Groves Dictionaries Inc, (19990000), pages 218 - 363 | - J.D. GRIFFIN et al., Leukemia Res.,, (19840000), vol. 8, page 521 | - O'KEEFE et al., J. Biol. Chem., (19850000), vol. 260, pages 932 - 937 | - C. ZAHND et al., Cancer Res., (20100000), vol. 70, pages 1595 - 1605 | - ZAHND et al., J. Biol. Chem., (20060000), vol. 281, no. 46, pages 35167 - 35175 | - BINZ, H.K.; AMSTUTZ, P.; PLUCKTHUN, A., Nature Biotechnology, (20050000), vol. 23, pages 1257 - 1268 | - P.A. MOORE et al., Blood, (20110000), vol. 117, no. 17, pages 4542 - 4551 | - VERI MC et al., Arthritis Rheum, (20100330), vol. 62, no. 7, pages 1933 - 43 | - JOHNSON S et al., J. Mol. Biol., (20100409), vol. 399, no. 3, pages 436 - 49 | - Methods in Enzymol, (20120000), vol. 502, pages 293 - 319 | - WARD et al., Nature, (19890000), vol. 341, pages 544 - 546 | - BIRD et al., Science, (19880000), vol. 242, pages 423 - 426 | - HUSTON et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, pages 5879 - 5883 | - HOLLIGER et al., Proc. Natl. Acad. Sci. USA, (19930000), vol. 90, pages 6444 - 6448 | - POLJAK et al., Structure, (19940000), vol. 2, pages 1121 - 1123 | - HU et al., Cancer Res., (19960000), vol. 56, pages 3055 - 3061 | - DIGIAMMARINO et al., Methods Mol. Biol., (20120000), vol. 899, pages 145 - 56 | - DESNOYERS et al., Sci. Transl. Med., (20130000), vol. 5, page 207ra144 | - WANG et al., Proc. Natl. Acad. Sci. USA, (20110000), vol. 108, no. 17, pages 6909 - 6914 | - DANE et al., Mol. Cancer. Ther., (20090000), vol. 8, no. 5, pages 1312 - 1318 | - BISSERY, M. et al., "Experimental Antitumor Activity of Taxotere (RP 56976, NSC 628503), a Taxol Analogue", Cancer Res, (19910900), vol. 51, pages 4845 - 4852 | US20100307797 | US20100346595 | US20100413172 |